Skip to content

Guselkumab

Interleukin-23 Antagonist — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: CNTO 1959, tremfya

EMA approvedFDA approvedPMDA approvedATC L04AC16

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Guselkumab is a drug in the Interleukin-23 Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Interleukin-23 Antagonists. DrugCentral lists 1 molecular target, including IL12B|IL23A. Recorded indications include Palmoplantar pustulosis and Plaque psoriasis.

  • Drug class: Interleukin-23 Antagonist.
  • Mechanism of action: Interleukin-23 Antagonists.
  • Molecular targets: IL12B|IL23A (1 listed in DrugCentral).
  • Indications: Palmoplantar pustulosis and Plaque psoriasis.
  • ATC code: L04AC16 (Interleukin inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Palmoplantar pustulosis
  • Plaque psoriasis

Mechanism & targets

Mechanism of action (MoA)Interleukin-23 Antagonists
Established pharmacologic classInterleukin-23 Antagonist

Molecular targets (1)

TargetGeneActionActivity
Interleukin-23IL12B|IL23Aother—

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2018-03-23PMDA—Janssen Pharmaceutical KK
2017-11-10EMA—Janssen-Cilag International N.V.
2017-07-13FDA—JANSSEN BIOTECH

ATC classification

ATC codeTherapeutic hierarchy
L04AC16ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Product dose omission issue16150.6
Accidental exposure to product4685.9
Needle issue4259.1
Device deployment issue2941.7
Device issue2705.1
Device malfunction2455.8
Product leakage2084.9
Device defective2054.4
Drug delivery system malfunction1911.3
Device leakage1665.0
Product storage error1156.4
Syringe issue732.5

Chemical structure

Molecular formula—
Molecular weight—
CAS number1350289-85-8
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Guselkumab used for?

DrugCentral lists the following indications for Guselkumab: Palmoplantar pustulosis and Plaque psoriasis.

How does Guselkumab work?

Guselkumab is classified as Interleukin-23 Antagonists; its molecular targets in DrugCentral include IL12B|IL23A.

When was Guselkumab first approved?

Guselkumab was first approved by the FDA in 2017.

What drug class does Guselkumab belong to?

Guselkumab is in the Interleukin-23 Antagonist class.

Browse: all drugs starting with G · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2017-07-13
AgencyFDA
Targets1
Indications2
Formula—
DrugCentral ID5246
Interactive profile